Profiel
Joshua Weiyuan Wang is the founder of PathoVax LLC, where he holds the title of Chief Executive Officer & Director since 2014.
Dr. Wang is also the founder of Verimmune, Inc.
Actieve functies van Joshua Weiyuan Wang
Bedrijven | Functie | Begin |
---|---|---|
PathoVax LLC
PathoVax LLC Miscellaneous Commercial ServicesCommercial Services PathoVax LLC engages in the provision of biotechnology services. It focuses on medical applications for its proprietary Papillomavirus Virus-like Particle platform. The company was founded by Joshua Wang, Weijie Poh, and Nicholas Calcaterra in 2014 and is headquartered in Baltimore, MD. | Oprichter | 01-01-2014 |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
PathoVax LLC
PathoVax LLC Miscellaneous Commercial ServicesCommercial Services PathoVax LLC engages in the provision of biotechnology services. It focuses on medical applications for its proprietary Papillomavirus Virus-like Particle platform. The company was founded by Joshua Wang, Weijie Poh, and Nicholas Calcaterra in 2014 and is headquartered in Baltimore, MD. | Commercial Services |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | Health Technology |